Premier Vein & Vascular Center: Houston's Leading Destination for Expert Vein & Fibroid Treatments
Premier Vein & Vascular Center, a trusted leader in vascular and fibroid treatments, is setting new standards for specialized care in Houston. With board-certified specialists and state-of-the-art, minimally invasive procedures, the clinic is dedicated to helping patients achieve relief from painful, unsightly vein conditions and fibroid-related discomfort.
Houston, TX - Premier Vein & Vascular Center, a leading vein clinic in Houston, is proud to offer a comprehensive range of cutting-edge, minimally invasive treatments for a variety of vein and vascular conditions. With over 20 years of experience, our board-certified vein doctors are dedicated to providing patient-centered care that focuses on both cosmetic improvements and long-term vascular health.
At Premier Vein & Vascular Center, patients have access to advanced treatments for varicose veins, using safe, gentle procedures to eliminate painful, bulging veins and restore confidence. Our vein clinic also specializes in spider vein treatment through highly effective sclerotherapy injections that leave the skin smooth and clear. Chronic pelvic pain caused by pelvic congestion syndrome is treated with advanced embolization techniques for lasting relief. For patients suffering from chronic knee pain, Genicular Artery Embolization (GAE) offers a minimally invasive option to help restore mobility. Women experiencing discomfort from uterine fibroids can benefit from Uterine Fibroid Embolization (UFE), a non-surgical procedure designed to reduce fibroids while preserving the uterus. In addition, our vein doctors offer expert care for venous ulcers with advanced healing therapies and compression treatments. Patients with Peripheral Arterial Disease (PAD) are treated using innovative procedures that restore healthy blood flow and improve function. For those diagnosed with Deep Vein Thrombosis (DVT), our clinic provides state-of-the-art care to dissolve dangerous blood clots and protect overall vascular health.
'Vein disorders are not just cosmetic—they can deeply affect a person's mobility and quality of life,' said Dr. Raza, one of Houston's leading vein doctors at Premier Vein & Vascular Center. 'At our vein clinic, we are committed to delivering advanced, minimally invasive solutions that help our patients return to pain-free, active living.'
Premier Vein & Vascular Center is proud to be an IAC-accredited vein clinic, recognized for meeting the highest standards of quality in vascular care. With two convenient Houston locations, patients benefit from same-week consultations and a smooth, expert-guided treatment process tailored to their needs.
Patients consistently rate Premier Vein & Vascular Center as Houston's top-rated vein clinic. Johanna Alejandre shared, 'Best staff ever! After 20 years, I can finally wear shorts again thanks to their varicose vein treatments.' Kayla LeMoine said, 'Dr. Raza and his team made me feel completely at ease. My procedure took only 10 minutes!' Rebecca Blake added, 'Highly professional and efficient. I recommend this clinic 110%!'
Premier Vein & Vascular Center is currently offering complimentary vein consultations for new patients. To schedule an appointment with an experienced vein doctor, call (832) 974-2329 or visit us at 19255 Park Row, Suite 201, Houston, TX 77084.
Media Contact
Email: Send Email
Phone: (832) 321-5355
Address:19255 Park Row Dr Suite 201
City: Houston
State: TX
Country: United States
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25-06-2025
- Yahoo
UFE Doesn't Remove Fibroids--Here's What Women Aren't Being Told
WASHINGTON, June 25, 2025 /PRNewswire/ -- Every year, thousands of women are steered toward a fibroid treatment that doesn't actually remove fibroids. Uterine Fibroid Embolization (UFE) may sound minimally invasive but it doesn't remove fibroids; it just shrinks them, slightly, often with disappointing results. At the Center for Innovative GYN Care (CIGC), we believe women deserve the truth—and real options—before making a decision that impacts their fertility, health, and future. "UFE may shrink fibroids slightly, but it rarely makes a meaningful difference—especially with large or complex cases," said Dr. Natalya Danilyants, board-certified GYN surgeon and co-founder of CIGC. "The fibroids are still inside your body, and so are the symptoms. For many women, the pain, pressure, and bleeding continue—or even worsen—because the root problem was never removed," she added. Fibroids are very common and affect approximately 80% of women…By age 50, about 80% of women will have fibroids." THE HIDDEN COSTS OF UFE Too many women are told UFE is their best option. But here's what they're not being told: Fibroids will remain in the body after UFE—and can grow back. Fertility can be reduced due to impaired blood flow to the uterus or ovaries. Large or complex fibroids? UFE often fails to relieve symptoms or prevent repeat procedures. Coexisting conditions like endometriosis or adenomyosis go undiagnosed—because UFE can't detect or treat them. UFE may delay the treatment you actually need. PROVEN ALTERNATIVE: COMPLETE REMOVAL, FASTER RECOVERY For more than 18 years, CIGC has been providing minimally invasive outpatient procedures that fully remove fibroids—even large, complex, or multiple growths—through just two tiny incisions: LAAM® Myomectomy: A fertility-sparing surgery that could improve your chances of getting pregnant. DualPortGYN®: Our advanced laparoscopic technique for hysterectomy or fibroid removal. 7–10 day recovery at home—not weeks in pain. Both options are performed in our surgical centers by board-certified GYN surgeons—and patients are able to go home the same day and be back to work in under two weeks. ONE SURGERY. REAL ANSWERS. Unlike UFE, our surgeons can also diagnose and remove endometriosis, cysts, or adenomyosis—and send all tissue to pathology for testing. That means you leave surgery knowing what was inside your body… and what wasn't. If you've been told your fibroids are "not that bad" or pushed toward a one-size-fits-all procedure like UFE, it's time to rethink your care. Book a consultation with a gynecologic surgeon to get answers—and take control of your health. "We believe women deserve much more than symptom management. They deserve validation, compassion, and swift resolution," said Dr. Danilyants. About the Center for Innovative GYN Care CIGC is a national leader in minimally invasive GYN surgery, with advanced surgical centers serving women across the DC, Maryland, Virginia (DMV) region and New Jersey. Our reputation for excellence draws patients from across the U.S. and around the world—thanks to our groundbreaking outpatient procedures, short recovery times, and life-changing results. Our board-certified, fellowship-trained surgeons specialize in the complete removal of complex fibroids, endometriosis, and chronic pelvic pain—with a singular focus on compassionate, patient-first care. Visit our website or follow us on Instagram or YouTube to learn more. Press Contact: Jasmin Ramsey PR & Marketing Managersocial@ View original content to download multimedia: SOURCE The Center for GYN Care
Medscape
24-06-2025
- Medscape
Semaglutide Shows Benefits for PAD Across T2D Subgroups
CHICAGO — Use of the GLP-1 receptor agonist semaglutide improved walking capability in patients with peripheral arterial disease (PAD) and type 2 diabetes (T2D), regardless of duration of diabetes, BMI, or glycemic control, a post-hoc analysis of phase 3 double-blind randomized STRIDE showed. 'PAD remains a recalcitrant problem in people living with diabetes. We need solutions for improving quality of life and preventing limb loss' said senior study author Subodh Verma, MD, PhD, a cardiovascular surgeon and professor of medicine at the University of Toronto, Canada, here at the American Diabetes Association (ADA) 85th Scientific Sessions, where the results were presented. The data was simultaneously published online in Diabetes Care . About 230 million people globally — and up to a third of those with diabetes — have PAD, which is why the ADA recommends using ankle-brachial index testing in individuals with T2D who are over 65 and meet certain criteria. The STRIDE Study STRIDE was conducted at 112 sites in 20 countries, enrolling 792 patients aged 18 years and older with T2D and PAD with intermittent claudication and reduced ankle-brachial or toe-brachial index. The median age was 68 years, the mean diabetes duration was 13.3 years, and 195 (25%) participants were female and 597 (75%) were male. Patients were randomized to subcutaneous semaglutide 1 mg per week for 52 weeks (n = 396) or to placebo (n = 396). The primary analysis of the trial, presented at the American College of Cardiology Scientific Session 2025 in March, showed that semaglutide significantly improved walking distance, pain, and quality of life in patients with symptomatic PAD and T2D. It was also associated with reductions in disease progression and use of rescue therapy and improvement in ankle-brachial index. At baseline, trial participants could walk a maximum of 184 m, and the pain-free walking distance was 119 m. Two-thirds of the individuals said PAD moderately-to-severely impacted quality of life. At week 52, patients taking once-weekly semaglutide had a roughly 40-m improvement in maximum walking distance, and a 30-m improvement in pain-free walking distance on a treadmill with a fixed speed of 3.2 kph (2.3 mph) and fixed inclination of 12%, when compared with placebo. For the current analysis, the researchers stratified the participants by baseline T2D characteristics. The mean BMI was 29.6; 41% had a BMI > 30, and 44% had A1C < 7%. Only a third used insulin and a third used an SGLT2 inhibitor. Their analysis showed no meaningful distinction between the subgroups for improvement in either maximum walking distance or pain-free walking distance, said lead author Neda Rasouli, MD, professor of medicine at the University of Colorado Anschutz Medical Campus, Aurora, at the meeting. The estimated treatment ratio favored semaglutide regardless of diabetes duration, BMI, A1C, or medication used, she added. These findings support semaglutide's 'consistent efficacy and safety profile across the spectrum of type 2 diabetes, including those who are non-obese and have well-controlled diabetes,' she concluded. Vascular Medications 'This was a really important study,' said Kim Eagle, MD, the Albion Walter Hewlett professor of internal medicine at the University of Michigan, when asked to comment by Medscape Medical News . Eagle said that while the additional 40 m of walking distance might not seem huge, it could be meaningful for a golfer, for instance, who could walk that much further to their ball, without a golf cart. 'We're still learning about the effects of GLP-1s,' said Eagle, who is also director of the Frankel Cardiovascular Center at the University of Michigan. 'They clearly affect vascular function,' he said, adding that the effects in PAD would be expected for the entire class. 'The thesis here is that these are vascular medications,' said Verma, noting in a briefing with reporters that patients had an improvement in hemodynamics. The improvement is not driven by changes in weight or A1C, he added. Given the results of STRIDE and the post-hoc analysis, 'I would suggest that it should be strongly considered by our patients living with PAD and diabetes as a strategy to not only improve MACE outcomes, but to also improve functional outcomes in PAD,' said Verma. Eagle noted, however, that clinicians often face barriers in prescribing GLP-1s. 'We're basically scrambling to see what's covered by patients' insurance,' he said. Verma and his co-authors said that more research is needed to understand if semaglutide's benefits extend to people with PAD who do not have diabetes. The study was funded by Novo Nordisk A/S. Rasouli reported receiving consultation fees and/or research funding from Novo Nordisk, Eli Lilly, Sanofi and SomaLogic. Verma disclosed research grants and/or speaking fees from Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, HLS Therapeutics, Anthos, Janssen, Novartis, Novo Nordisk, Pfizer, PhaseBio, S&L Solutions Event Management, and Sanofi. Eagle reported no relevant conflicts.
Yahoo
21-05-2025
- Yahoo
Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis
– Virtual KOL Event Tuesday, June 3, 2025 3:00pm ET – – Attend the event here: – LOS ANGELES, CA, May 21, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ('ImmixBio', 'Company', 'We' or 'Us' or 'IMMX'), clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that it will host a virtual Key Opinion Leader (KOL) event to discuss interim clinical data from the NEXICART-2 Phase 1/2 clinical trial of cell therapy NXC-201 in patients with relapsed/refractory AL Amyloidosis following its 2025 American Society of Clinical Oncology (ASCO) Oral Presentation in Chicago, IL. The virtual KOL event will take place on Tuesday, June 3, 2025 at 3:00pm ET. A live question and answer session will follow the discussion. The event will feature Heather Landau, MD (Memorial Sloan-Kettering Cancer Center), Shahzad Raza, MD (Cleveland Clinic), and Jeffrey Zonder, MD (Karmanos Cancer Institute) who will discuss their clinical experience with NXC-201 cell therapy and the evolving treatment landscape for relapsed/refractory AL Amyloidosis. Investors and other interested parties may join the live webcast through this weblink or visit the Immix website under Presentations & Events. About Heather Landau, MDHeather Landau, MD, is the Director of Amyloidosis Program and a Bone Marrow Transplant Specialist & Cellular Therapist at Memorial Sloan-Kettering Cancer Center in New York, with extensive experience designing clinical trials in hematology and oncology, novel treatment approaches for AL amyloidosis, and thought leadership. Dr. Landau has authored more than 100 peer-reviewed publications. Dr. Landau received her medical degree from SUNY Upstate Medical University, completed her Internal Medicine residency at University of Colorado and her Hematology & Oncology fellowship at Memorial Sloan Kettering Cancer Center. Dr. Landau is board certified in Internal Medicine, Medical Oncology and Hematology. About Shahzad Raza, MDShahzad Raza, MD is a hematologist/oncologist at Cleveland Clinic specializing in plasma cell dyscrasias, including AL Amyloidosis. Dr. Raza has authored numerous peer-reviewed publications over the last decade in academic medical practice. Dr. Raza completed his residency in internal medicine at the Brookdale Hospital Medical Center and his fellowship at the University of Missouri Hospitals & Clinics. About Jeffrey Zonder, MDJeffrey Zonder, MD leads the Amyloidosis multi-disciplinary team at the Barbara Ann Karmanos Cancer Institute. He is Professor, Department of Oncology, Wayne State University School of Medicine, Detroit, MI. Dr Zonder is also the co-leader and a scientific member of the Molecular Therapeutics Program at the Barbara Ann Karmanos Cancer Institute. Dr. Zonder received his medical degree from Wayne State University, completed his residency at Strong Memorial Hospital of the Univ. of Rochester and his fellowship at Wayne State University. About NEXICART-2NEXICART-2 (NCT06097832) is an ongoing single-arm multi-site U.S. Phase 1/2 clinical trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory AL Amyloidosis. NEXICART-2 is expected to enroll 40 patients with preserved heart function (excluding patients with pre-existing heart failure) who have not been exposed to prior BCMA-targeted therapy. The primary endpoint of the Phase 1 portion is safety. The primary endpoint of the Phase 2 portion is efficacy. About NXC-201NXC-201 is a sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy with a 'digital filter' that filters out non-specific activation. Initial data from ex-U.S. study NEXICART-1 has demonstrated high complete response rates in relapsed/refractory AL Amyloidosis. U.S. Phase 1/2 study NEXICART-2 is ongoing. NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the FDA, and Orphan Drug Designation (ODD) by the US FDA and in the EU by the EMA. About AL AmyloidosisAL amyloidosis is caused by abnormal plasma cells in the bone marrow, which produce misfolded amyloid proteins that build-up in the heart, kidney, liver, and other organs. This build-up causes progressive and widespread organ damage, including heart and renal failure, leading to high mortality rates. The U.S. observed prevalence of relapsed/refractory AL Amyloidosis is estimated to be growing at 12% per year according to Staron, et al Blood Cancer Journal, to approximately 33,277 patients in 2024. The Amyloidosis market was $3.6 billion in 2017, and is expected to reach $6 billion in 2025, according to Grand View Research. About Immix Biopharma, Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201. NXC-201 is being evaluated in the U.S. study NEXICART-2 (NCT06097832) as well as the ex-U.S. study NEXICART-1 (NCT04720313). NXC-201 has demonstrated no neurotoxicity in AL Amyloidosis, supporting expansion into other serious diseases. NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA. Learn more at and Forward Looking StatementsThis press release contains forward-looking statements regarding Immix Biopharma, Inc., its results of operations, prospects, future business plans and operations and the matters discussed above, including, but not limited to, the potential benefits of our product candidate CAR-T NXC-201 and the timing and results related clinical trials. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements also include, but are not limited to, our plans, objectives, expectations and intentions and other statements that contain words such as 'expects', 'contemplates', 'anticipates', 'plans', 'intends', 'believes', 'estimates', 'potential', and variations of such words or similar expressions that convey the uncertainty of future events or outcomes, or that do not relate to historical matters. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the further data from the ongoing Phase 1/2 clinical trials for CAR-T NXC-201 will not be favorably consistent with the data readouts to date, (ii) the risk that the Company may not be able to continue the NEXICART-2 multi-site U.S. Phase 1/2 clinical trial; (iii) the risk that the Company may not be able to advance to registration-enabling studies for CAR-T NXC-201 or other product candidates, (iv) that success in early phases of pre-clinical and clinicals trials do not ensure later clinical trials will be successful; (v) that no drug product developed by the Company has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (vi) the risk that the Company may not be able to obtain additional working capital with which to continue the clinical trials for CAR-T NXC-201, or advance to the initiation of registration-enabling studies, for such product candidates as and when needed and (vii) those other risks disclosed in the section 'Risk Factors' included in the Company's Annual Report on Form 10-K filed with the SEC on March 25, 2025 and other periodic reports subsequently filed with the Securities and Exchange Commission. These reports are available at Immix Biopharma cautions that the foregoing list of important factors is not complete. Immix Biopharma cautions readers not to place undue reliance on any forward-looking statements. Immix Biopharma does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. ContactsMike MoyerLifeSci Advisorsmmoyer@ Company Contactirteam@
